🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

203 results for “Novartis” Clear

  1. VAY736, ENTECAVIR , Placebo to VAY736, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -

    Novartis Ophthalmics Europe

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  2. YTB323, TISAGENLECLEUCEL, PHE885

    Novartis Ophthalmics Europe

    All patients who have been treated with Novartis or Penn CAR T-cell therapy for any indication

    phase 3 small molecule active

    1 trial

  3. Zolgensma 2 × 10^13 vector genomes/mL solution for infusion

    Novartis Ophthalmics Europe

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  4. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Ophthalmics Europe

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

  5. 00 mg/mL Concentrate for solution for infusion, VHB937

    Novartis Ophthalmics Europe

    Alzheimer’s disease

    phase 2 small molecule active

    1 trial

  6. A Phase I, open-label, multi-center exploratory safety and efficacy study with PSMA, SSTR2 and GRPR targeted radioligand therapy in metastatic neuroendocrine prostate cancer

    Novartis Ophthalmics Europe

    Metastatic neuroendocrine prostate cancer

    phase 2 other active

    1 trial

  7. ABIRATERONE, DAROLUTAMIDE, DZR123, -, -, ABIRATERONE, DZR123, DAROLUTAMIDE

    Novartis Ophthalmics Europe

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  8. ALPELISIB, FULVESTRANT, ALPELISIB, LETROZOLE, LEUPRORELIN ACETATE, GOSERELIN

    Novartis Ophthalmics Europe

    Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer

    phase 2 small molecule active

    1 trial

  9. ALPELISIB, RIBOCICLIB, LETROZOLE, LEE011, ALPELISIB, LEE011

    Novartis Ophthalmics Europe

    Advanced HR+ breast cancer

    phase 2 small molecule active

    1 trial

  10. AMO959, ENZALUTAMIDE, Enzalutamide, Prednison 5 mg GALEN® Tabletten, -, DEGARELIX, RELUGOLIX, Prednison acis 5 mg, Pluvicto 1 000 MBq/mL solution for injection/infusion, ABIRATERONE, Abiraterone, PIFLUFOLASTAT (18F), AMO959, GOZETOTIDE, DEGARELIX

    Novartis Ophthalmics Europe

    PSMA-positive mCRPC with prior exposure to at least one prior ARPI

    phase 2 small molecule active

    1 trial

  11. ASCIMINIB, ASCIMINIB HYDROCHLORIDE, Asciminib

    Novartis Ophthalmics Europe

    Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors

    phase 2 small molecule active

    1 trial

  12. Abraxane, CAAA614A12101, PACLITAXEL ALBUMIN-BOUND, OXALIPLATIN, FLUOROURACIL, AAA614, IRINOTECAN, AAA514, CALCIUM FOLINATE

    Novartis Ophthalmics Europe

    Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)

    phase 2 small molecule active

    1 trial

  13. Asciminib, ASCIMINIB HYDROCHLORIDE

    Novartis Ophthalmics Europe

    Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation

    phase 2 small molecule active

    1 trial

  14. BYL719, BYL719, BYL719

    Novartis Ophthalmics Europe

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  15. BYL719, BYL719, BYL719, BYL719, BYL719

    Novartis Ophthalmics Europe

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  16. Bion 1301/FUB523

    Novartis Ophthalmics Europe

    IgA nephropathy

    phase 2 small molecule active

    1 trial

  17. CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN

    Novartis Ophthalmics Europe

    Breast Cancer

    phase 2 small molecule active

    1 trial

  18. CPK850

    Novartis Ophthalmics Europe

    Retinitis pigmentosa caused by biallelic mutations in the RLBP1 gene

    phase 2 small molecule active

    1 trial

  19. CYCLOPHOSPHAMIDE, MYCOPHENOLATE MOFETIL, TACROLIMUS, YTB323, CYCLOPHOSPHAMIDE, RITUXIMAB, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TOCILIZUMAB, RITUXIMAB

    Novartis Ophthalmics Europe

    Severe refractory idiopathic inflammatory myopathies (IIM)

    phase 2 small molecule active

    1 trial

  20. CYCLOPHOSPHAMIDE, YTB323, FLUDARABINE PHOSPHATE, TOCILIZUMAB, RITUXIMAB, RITUXIMAB

    Novartis Ophthalmics Europe

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  21. DANAZOL , -, -, -, ENTECAVIR , -, VAY736

    Novartis Ophthalmics Europe

    Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)

    phase 2 small molecule active

    1 trial

  22. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Ophthalmics Europe

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  23. DEGARELIX, -, RELUGOLIX, ABIRATERONE, DEGARELIX, Luxdegalutamide, ABIRATERONE, ABIRATERONE, Abiraterone, ENZALUTAMIDE, ABIRATERONE, Enzalutamide

    Novartis Ophthalmics Europe

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  24. DFV890, DFV890, Placebo to MAS825 100 mg/1 mL Solution for Injection, Placebo to DFV890 10 mg and 25 mg film-coated tablet, MAS825

    Novartis Ophthalmics Europe

    Atherosclerotic cardiovascular disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources